IMMVF News Alert Immuno Vaccine Inc (IMMVF) 0.7260 09/20/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Immuno Vaccine Inc (IMMVF) 0.7260 $IMMVF

Global Ebola and Marburg Infections Therapeutics Pipeline Report 2014 - 10 Companies & 12 Drug Profiles
M2 - Tue Sep 09, 9:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gjrkc2/ebola_and_marburg) has announced the addition of the "Ebola and Marburg Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ebola and Marburg Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ebola and Marburg Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Crucell N.V. - NanoViricides, Inc. - AlphaVax, Inc. - Immunovaccine, Inc. - Integrated BioTherapeutics, Inc. - Profectus BioSciences, Inc. - Mapp Biopharmaceutical, Inc. Drug Profiles - Vaccine for Multivalent Filovirus - Ebola Vaccine Marburg Vaccine - Vaccine For Filovirus - Ebola/Marburg Program - Ebola And Marburg Vaccine - Monoclonal Antibody for Marburg Virus - Polyvalent DNA Vaccine for Ebola and Marburg Filoviruses - MVA-BN-Filoviruses Vaccine - rVSV-Vectored Vaccines - Subunit Vaccine for Multifiloviruses - Monoclonal Antibodies to Inhibit Glycoprotein for Marburg Virus Infection - Monoclonal Antibodies for Ebola and Marburg Infections For more information visit http://www.researchandmarkets.com/research/gj...nd_marburg

IIROC Trade Resumption - Immunovaccine Inc.
Newsfile Corp - Tue Aug 26, 1:20PM CDT
Trading resumes in:

IIROC Trade Halt - Immunovaccine Inc.
Newsfile Corp - Tue Aug 26, 7:08AM CDT
The following issues have been halted by IIROC:

Ebola Vaccine Using Immunovaccine's DepoVax Proves Highly Efficacious in Non-Human Primate Study
Marketwire - Mon Aug 25, 9:31AM CDT
Immunovaccine Inc. ("Immunovaccine" (TSX VENTURE: IMV), a clinical stage vaccine company, today announced positive results for a vaccine formulated in its DepoVax(TM) technology in an Ebola virus challenge study performed by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). In a preliminary study using cynomolgus monkeys, which are particularly sensitive to the Ebola virus, all vaccinated subjects survived exposure to a lethal dose of the wild type Zaire strain of the virus. All unvaccinated control animals succumbed to the disease.

Immunovaccine Announces Financial Results for Quarter Ended June 30, 2014
Marketwire - Fri Aug 15, 7:06AM CDT
Immunovaccine Inc. ("Immunovaccine" or "IMV" (TSX VENTURE: IMV), a clinical stage vaccine company, today released its financial and operational results for the quarter ended June 30, 2014.

Immunovaccine to Present at Ninth Annual Immunotherapies and Vaccines Summit (ImVacS) Conference
Marketwire - Tue Aug 12, 7:06AM CDT
Immunovaccine Inc. ("Immunovaccine" or "IMV" (TSX VENTURE: IMV), a clinical stage vaccine company, announced today that Marc Mansour, Ph.D., the Company's chief executive officer, will make a presentation at the Ninth Annual Immunotherapies and Vaccines Summit (ImVacS). In addition to his presentation, Dr. Mansour will also serve as chairperson of the conference's "Clinical Updates of Combination Immunotherapies" session. The conference will take place on August 11-14, 2014 at the Marriott Long Wharf Hotel in Boston, MA.

Immunovaccine and Pfenex Report Positive Results from Single Dose Anthrax Vaccine Studies
Marketwire - Tue Apr 01, 7:06AM CDT
Immunovaccine Inc. ("Immunovaccine" (TSX VENTURE: IMV) and Pfenex Inc. ("Pfenex" today announced positive results from anthrax challenge studies in rabbits using Pfenex's mutant recombinant Protective Antigen (mrPA) formulated with Immunovaccine's DepoVax(TM) delivery system. The studies showed that animals administered a vaccine containing mrPA formulated in DepoVax were protected against a lethal anthrax challenge at a range of antigen doses.

Immunovaccine Announces 2013 Year-End Results
Marketwire - Mon Mar 17, 7:06AM CDT
Immunovaccine Inc. (TSX VENTURE: IMV), a clinical stage vaccine company, today announced its financial and operational results for the year ended December 31, 2013.

MediMabs Announces the Appointment of Two New Members of the Board of Directors
Marketwire - Thu Feb 20, 10:52AM CST
Ms. Sarita Benchimol, the President and Chief Executive Officer of MediMabs Inc., is pleased to announce the election to the MediMabs Board of Directors of Dr. Randal Chase PhD and Mr. R Martin Wong CPA, CA. Both individuals were elected at the company's shareholder meeting and will be joining the existing board of directors, which includes Dr. Phil Gold CC, OQ, MD, PhD, FRSCopyright, FRCPCopyright, MACP, Dr. Claudio Cuello OC, MD, DSc, FRSCopyright, Mr. Miguel Madanes Eng., and Ms. Sarita Benchimol MSc.

Ebola and Marburg Infections - Pipeline Review, H2 2013 Report
M2 - Tue Feb 04, 2:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/bv7mx8/ebola_and_marburg) has announced the addition of the "Ebola and Marburg Infections - Pipeline Review, H2 2013" report to their offering. 'Ebola and Marburg Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ebola and Marburg Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ebola and Marburg Infections. Scope - A snapshot of the global therapeutic scenario for Ebola and Marburg Infections. - A review of the Ebola and Marburg Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ebola and Marburg Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Inovio Pharmaceuticals, Inc. Bavarian Nordic A/S Crucell N.V. NanoViricides, Inc. SIGA Technologies, Inc. Functional Genetics, Inc. Okairos AG AlphaVax, Inc. Immunovaccine, Inc. Mapp Biopharmaceutical, Inc. For more information visit http://www.researchandmarkets.com/research/bv...nd_marburg About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Immunovaccine Inc names Dr Llew Keltner to board
M2 - Tue Jan 21, 4:13AM CST
Immunotherapy company Immunovaccine Inc (TSX VENTURE:IMV) reported on Monday the addition of Dr Llew Keltner, MD, PhD to its board of directors with immediate effect.

Llew Keltner, US Biotech Industry Adviser, Joins Board of Immunovaccine
Marketwire - Mon Jan 20, 7:08AM CST
Immunovaccine Inc. ("Immunovaccine" or "IMV" or "the Company" (TSX VENTURE: IMV), a clinical stage vaccine and immunotherapy company, has elected Llew Keltner, M.D., Ph.D. to its board of directors. The appointment is effective immediately.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 407

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 119

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
Luca's Campo Morado Denial Makes Guerrero Risk Clear

Updated Category News Views 94

A Dangerous Headline Needs More Than a Quick Rebuttal One ugly allegation can do more damage to a junior miner than a lousy quarter, especially when it involves a mine in Guerrero State and alleged criminal control. Luca Mining has flatly rejected Mexican media reports claiming that its Campo Morado Mine is controlled by a criminal organization. The company says the...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 292

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 481

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Australia Leads TTW's 2027 Global Travel Country List

Updated Category News Views 75

A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 570

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 478

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 91

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 130

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading

Top 5 Most Recently Viewed Articles

Trump Ventures into Cryptocurrency: A Challenging Transition

Updated Category News Views 79

Trump's Shift Towards Cryptocurrency In an unexpected move, Donald Trump has made headlines by stepping into the cryptocurrency market. This shift has drawn both curiosity and skepticism, especially since Trump had previously labeled Bitcoin as a "scam." Many are now questioning if he truly understands the intricacies of the cryptocurrency world he now supports. World...

Continue Reading
IPG Photonics Announces Upcoming Financial Results Event

Updated Category News Views 147

IPG Photonics Scheduled to Release Third Quarter Results IPG Photonics Corporation (Nasdaq: IPGP) is poised to announce its third quarter financial results on November 4, 2025. This event is anticipated to shed light on the Company’s performance and future outlook. Before the market opens that day, IPG will share its financial results, providing investors and...

Continue Reading
Willdan Group Achieves Significant Growth with New Projects

Updated Category News Views 49

Willdan Group Soars to New Heights Willdan Group Inc. (NASDAQ: WLDN) recently celebrated a remarkable achievement as its stock soared to a 52-week high of $41.58. This milestone is not just a number; it represents the confidence that investors have in the company, showcasing a tremendous 109.11% increase in its stock price over the last year. Such significant growth...

Continue Reading
International Paper's Commitment to Shareholders Deepens with Dividends

Updated Category News Views 108

International Paper's Quarterly Dividend Announcement International Paper (NYSE: IP) has reaffirmed its dedication to its shareholders with the announcement of substantial quarterly dividends. Recently, the company declared a dividend of $0.4625 per share, covering the period from the start of January to the end of March of this year. This payment reflects the...

Continue Reading